Neurotrope and Metuchen Merge to Form Petros Pharmaceuticals

Novaremed AG Acquires Metys Pharmaceuticals AG

September 7, 2021

Pharmaceuticals

Novaremed AG acquired Metys Pharmaceuticals AG in an all-share transaction, integrating Metys' clinical and preclinical non-opioid pain programs (including MP-101 and MP-103) into Novaremed's pipeline. The deal broadens Novaremed's focus from painful diabetic peripheral neuropathy (PDPN) to include chemotherapy-induced peripheral neuropathy (CIPN) and strengthens leadership with the election of Andrew J. Oakley to Novaremed's board.

N-Power Medicine Acquires Syapse

December 30, 2024

Healthcare Services

N-Power Medicine completed a stock-for-stock acquisition of Syapse on December 30, 2024, integrating Syapse’s precision-medicine technology, data assets and network of community oncologists into N-Power’s Kaleido Registry and AI-enabled point-of-care platform. Innovatus Capital Partners joined N-Power’s existing investors (including the Merck Global Health Innovation Fund) to provide ongoing funding; Canaccord Genuity served as Syapse’s exclusive financial advisor.

CBC Group and Mubadala Acquire UCB's Mature China Neurology & Allergy Portfolio to Create NeuroGen Pharma

November 29, 2024

Pharmaceuticals

CBC Group, in partnership with Mubadala Investment Company, has completed the US$680 million acquisition of UCB’s mature neurology and allergy product portfolio in China, including brands such as Keppra, Vimpat, Neupro, Zyrtec and Xyzal and a manufacturing site in Zhuhai. The assets have been combined into a new company named NeuroGen Pharma as an anchor platform to build an integrated CNS biopharma business in China and expand capability in neurology and allergy treatments.

EmergentMedTech Merges with TRU Biologix

January 22, 2025

Biotechnology

EmergentMedTech announced a merger with TRU Biologix to integrate TRU Biologix's Wharton's Jelly–derived cell and tissue biologics into EmergentMedTech's regenerative medicine and aesthetics product portfolio. The deal expands EmergentMedTech's capabilities alongside its role as the exclusive U.S. distributor of NeoGen PSR, enabling delivery of advanced biologics to hundreds of clinics and clinician partners.

Chroma Medicine and Nvelop Therapeutics Merge to Form nChroma Bio

December 11, 2024

Biotechnology

Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio and completed an oversubscribed $75 million financing led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture and Newpath Partners. The combined company will advance a pipeline built on epigenetic editing and non-viral, programmable in vivo delivery, with lead candidate CRMA-1001 targeted at chronic hepatitis B and D and a planned clinical trial application submission in 2025.

Manna Pro Products Acquires Nutri-Vet and Petnology Essentials

December 14, 2015

Consumer Products

Chesterfield, Missouri-based Manna Pro Products LLC has acquired Nutri-Vet LLC of Boise, Idaho, along with the Petnology Essentials product line from 21st Century HealthCare Inc. The deals expand Manna Pro's portfolio into the cat and dog supplement market, with the acquired brands operating together as Nutri-Vet Wellness LLC; terms were not disclosed.